New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care - Scorecard - MDSpire

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • By

  • May 26, 2026

  • 5 min

Share

Clinical Scorecard: New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAverage-risk women ages 50 to 74, with considerations for high-risk patients.
Care Setting

Key Highlights

  • ACP recommends biennial mammography for average-risk women ages 50 to 74, with individualized strategies for high-risk patients.

Guideline-Based Recommendations

Diagnosis

  • Mammography should be available starting at age 40, with individualized assessments for high-risk patients.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Consideration of supplemental imaging for patients with dense breast tissue or elevated risk, emphasizing the need for formal risk assessment.

        Clinical Best Practices

        • Ensure individualized clinical judgment in screening recommendations.
        • Address disparities in access to screening and risk assessment.
        • Provide ongoing education about disparities in access to care.

        Related Resources & Content

        Original Source(s)

        New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

        • by

        • May 26, 2026

        Related Content

        When Insight Meets Urgency in Cell and Gene Therapy

        Balancing deep biological insight with the realities of development is now central to progress in advanced medicine

        This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

        Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward

        • May 26, 2026

        • 9 min
        Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

        Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...